Which has higher earnings & valuation, GOVX or LGVN?

GeoVax Labs has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs $2.49M 1.87 -$21.47M -$19.12 N/A Longeveron $1.22M 21.01 -$22.70M -$1.13 N/A

Is GOVX or LGVN more profitable?

GeoVax Labs has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Longeveron -1,844.49% -202.41% -140.67%

Does the media prefer GOVX or LGVN?

In the previous week, GeoVax Labs and GeoVax Labs both had 2 articles in the media. Longeveron's average media sentiment score of 0.85 beat GeoVax Labs' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GOVX or ALVR?

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 11,094.03%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, GOVX or ALVR?

GeoVax Labs has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs $2.49M 1.87 -$21.47M -$19.12 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is GOVX or ALVR more profitable?

AlloVir's return on equity of -71.03% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% AlloVir N/A -71.03% -61.27%

Do analysts rate GOVX or VYNE?

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 11,094.03%. Given GeoVax Labs' higher possible upside, research analysts plainly believe GeoVax Labs is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is GOVX or VYNE more profitable?

GeoVax Labs has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% VYNE Therapeutics -4,726.21% -70.42% -63.46%

Does the media favor VTGN or GOVX?

In the previous week, VistaGen Therapeutics had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 2 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.00 beat VistaGen Therapeutics' score of -1.00 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CLRB or GOVX more profitable?

Cellectar Biosciences' return on equity of -349.24% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% GeoVax Labs N/A -709.52% -399.33%

Does the media prefer CLRB or GOVX?

In the previous week, Cellectar Biosciences and Cellectar Biosciences both had 2 articles in the media. Cellectar Biosciences' average media sentiment score of 0.37 beat GeoVax Labs' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GeoVax Labs (GOVX) Competitors

$1.34 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$1.34 0.00 (0.00%)

As of 06/18/2026 07:57 PM Eastern

Compare

GOVX vs. LGVN, ALVR, VYNE, VTGN, and CLRB

Should you buy GeoVax Labs stock or one of its competitors? MarketBeat compares GeoVax Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeoVax Labs include Longeveron (LGVN), AlloVir (ALVR), VYNE Therapeutics (VYNE), VistaGen Therapeutics (VTGN), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry.

How does GeoVax Labs compare to Longeveron?

GeoVax Labs (NASDAQ:GOVX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

GeoVax Labs has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Longeveron	-1,844.49%	-202.41%	-140.67%

GeoVax Labs has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.87	-$21.47M	-$19.12	N/A
Longeveron	$1.22M	21.01	-$22.70M	-$1.13	N/A

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 7.4% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GeoVax Labs has a beta of 3.62, meaning that its stock price is 262% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market.

GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 11,094.03%. Longeveron has a consensus target price of $5.50, suggesting a potential upside of 570.65%. Given GeoVax Labs' higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than Longeveron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, GeoVax Labs and GeoVax Labs both had 2 articles in the media. Longeveron's average media sentiment score of 0.85 beat GeoVax Labs' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Longeveron beats GeoVax Labs on 9 of the 15 factors compared between the two stocks.

How does GeoVax Labs compare to AlloVir?

GeoVax Labs (NASDAQ:GOVX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

AlloVir's return on equity of -71.03% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
AlloVir	N/A	-71.03%	-61.27%

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 11,094.03%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GeoVax Labs has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.87	-$21.47M	-$19.12	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

In the previous week, GeoVax Labs had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for AlloVir. GeoVax Labs' average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
GeoVax Labs	Neutral
AlloVir	Neutral

GeoVax Labs has a beta of 3.62, suggesting that its share price is 262% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Summary

GeoVax Labs beats AlloVir on 8 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to VYNE Therapeutics?

GeoVax Labs (NASDAQ:GOVX) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

GeoVax Labs has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.87	-$21.47M	-$19.12	N/A
VYNE Therapeutics	$570K	37.18	-$26.48M	-$0.38	N/A

In the previous week, GeoVax Labs had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for VYNE Therapeutics. GeoVax Labs' average media sentiment score of 0.00 equaled VYNE Therapeutics'average media sentiment score.

Company	Overall Sentiment
GeoVax Labs	Neutral
VYNE Therapeutics	Neutral

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 11,094.03%. Given GeoVax Labs' higher possible upside, research analysts plainly believe GeoVax Labs is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

GeoVax Labs has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

GeoVax Labs has a beta of 3.62, suggesting that its stock price is 262% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market.

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

GeoVax Labs and VYNE Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does GeoVax Labs compare to VistaGen Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 0.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

VistaGen Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 41.75%. GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 11,094.03%. Given GeoVax Labs' higher possible upside, analysts clearly believe GeoVax Labs is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

GeoVax Labs has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	21.65	-$51.42M	-$1.83	N/A
GeoVax Labs	$2.49M	1.87	-$21.47M	-$19.12	N/A

GeoVax Labs has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
GeoVax Labs	N/A	-709.52%	-399.33%

VistaGen Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.62, meaning that its stock price is 262% more volatile than the broader market.

In the previous week, VistaGen Therapeutics had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 2 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.00 beat VistaGen Therapeutics' score of -1.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

VistaGen Therapeutics beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

How does GeoVax Labs compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Cellectar Biosciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.62, meaning that its stock price is 262% more volatile than the broader market.

Cellectar Biosciences' return on equity of -349.24% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
GeoVax Labs	N/A	-709.52%	-399.33%

Cellectar Biosciences currently has a consensus price target of $11.00, indicating a potential upside of 294.27%. GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 11,094.03%. Given GeoVax Labs' higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Cellectar Biosciences and Cellectar Biosciences both had 2 articles in the media. Cellectar Biosciences' average media sentiment score of 0.37 beat GeoVax Labs' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeoVax Labs has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
GeoVax Labs	$2.49M	1.87	-$21.47M	-$19.12	N/A

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cellectar Biosciences beats GeoVax Labs on 8 of the 13 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOVX vs. The Competition

Export

Metric	GeoVax Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.65M	$3.41B	$6.42B	$12.59B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-0.07	19.73	24.78	24.44
Price / Sales	1.87	317.97	549.86	123.14
Price / Cash	N/A	127.84	45.07	55.09
Price / Book	0.61	8.16	10.80	6.58
Net Income	-$21.47M	$23.94M	$3.57B	$337.17M
7 Day Performance	9.84%	2.57%	0.72%	0.83%
1 Month Performance	-51.27%	0.69%	0.41%	2.25%
1 Year Performance	-94.32%	55.09%	29.34%	36.14%

GeoVax Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOVX GeoVax Labs	1.7751 of 5 stars	$1.34 flat	$150.00 +11,094.0%	-94.3%	$4.65M	$2.49M	N/A	10	Analyst Upgrade Gap Down
LGVN Longeveron	2.786 of 5 stars	$0.75 +3.3%	$5.50 +629.4%	-31.7%	$22.74M	$1.20M	N/A	20	News Coverage Gap Up
ALVR AlloVir	N/A	$4.44 -4.7%	N/A	+83.7%	$22.39M	N/A	N/A	110	High Trading Volume
VYNE VYNE Therapeutics	0.8266 of 5 stars	$0.66 +0.4%	N/A	-28.6%	$21.88M	$570K	N/A	30
VTGN VistaGen Therapeutics	1.5424 of 5 stars	$0.54 -1.2%	$0.95 +76.8%	-66.5%	$21.55M	$490K	N/A	40	Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOVX) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeoVax Labs (GOVX) Competitors

GOVX vs. LGVN, ALVR, VYNE, VTGN, and CLRB

How does GeoVax Labs compare to Longeveron?

Summary

How does GeoVax Labs compare to AlloVir?

Summary

How does GeoVax Labs compare to VYNE Therapeutics?

Summary

How does GeoVax Labs compare to VistaGen Therapeutics?

Summary

How does GeoVax Labs compare to Cellectar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeoVax Labs (GOVX) Competitors

GOVX vs. LGVN, ALVR, VYNE, VTGN, and CLRB

How does GeoVax Labs compare to Longeveron?

Is GOVX or LGVN more profitable?

Which has higher earnings & valuation, GOVX or LGVN?

Do institutionals & insiders hold more shares of GOVX or LGVN?

Which has more risk & volatility, GOVX or LGVN?

Do analysts rate GOVX or LGVN?

Does the media prefer GOVX or LGVN?

Summary

How does GeoVax Labs compare to AlloVir?

Is GOVX or ALVR more profitable?

Do institutionals & insiders believe in GOVX or ALVR?

Do analysts rate GOVX or ALVR?

Which has preferable earnings & valuation, GOVX or ALVR?

Does the media refer more to GOVX or ALVR?

Which has more risk & volatility, GOVX or ALVR?

Summary

How does GeoVax Labs compare to VYNE Therapeutics?

Which has better earnings & valuation, GOVX or VYNE?

Does the media prefer GOVX or VYNE?

Do analysts rate GOVX or VYNE?

Is GOVX or VYNE more profitable?

Which has more risk and volatility, GOVX or VYNE?

Do institutionals and insiders hold more shares of GOVX or VYNE?

Summary

How does GeoVax Labs compare to VistaGen Therapeutics?

Do insiders & institutionals believe in VTGN or GOVX?

Do analysts recommend VTGN or GOVX?

Which has higher valuation and earnings, VTGN or GOVX?

Is VTGN or GOVX more profitable?

Which has more risk & volatility, VTGN or GOVX?

Does the media favor VTGN or GOVX?

Summary

How does GeoVax Labs compare to Cellectar Biosciences?

Which has more volatility & risk, CLRB or GOVX?

Is CLRB or GOVX more profitable?

Do analysts recommend CLRB or GOVX?

Does the media prefer CLRB or GOVX?

Which has stronger valuation & earnings, CLRB or GOVX?

Do institutionals and insiders believe in CLRB or GOVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools